Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626002 · ClinicalTrials.gov registry record · Phase 3
Open Label Continuation Study in Moderate to Severe Psoriasis
A Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,301
- Enrollment target
NCT00626002 is a Phase 3 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 2,301 participants.
The verdict
NCT00626002, a Phase 3 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,301 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
Interventions
- DRUG ABT-874
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,301 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626002
The ClinicalTrials.gov registry entry for NCT00626002 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-874 is the first listed.
NCT00626002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626002 about?
NCT00626002 is a clinical study titled "Open Label Continuation Study in Moderate to Severe Psoriasis". The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
What is the current status of trial NCT00626002?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,301 participants. The study started on 2008-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00626002?
The interventions under investigation include: ABT-874 (DRUG).
Who is sponsoring clinical trial NCT00626002?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.